# TherapeuticsMD, Inc. (TXMD)

> Source: Nexqual · https://nexqual.com/TXMD · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, TherapeuticsMD, Inc. (TXMD), nexqual.com/TXMD" · informational, not investment advice.

**Price:** USD 1.93 (-2.03% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.97 · day 1.92–1.98 · 52w 1.05–2.95 · market cap $22.3M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $3.3M, net income -$217K (-6.6% margin) (SEC filings).
- Total return with dividends: 1Y +83.8% vs S&P 500 +18.1%; 5Y -94.6% vs S&P 500 +85.1%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2023 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.6M | $70.0M | $1.3M | $1.8M | $3.0M | $3.3M |
| Gross profit | $1.2M | $68.6M | $1.3M | — | — | — |
| Operating income | -$79.6M | $1.2M | -$8.5M | -$6.1M | -$4.4M | -$4.0M |
| Net income | -$172M | $112M | -$10.3M | -$2.2M | -$569K | -$217K |
| EPS (diluted) | -$21.66 | $11.96 | -$0.99 | -$0.19 | -$0.05 | — |
| Free cash flow | -$143M | — | — | — | — | — |
| Gross margin | 45.5% | 98.0% | 100.0% | — | — | — |
| Operating margin | -3092.8% | 1.7% | -654.6% | -347.1% | -145.3% | -120.9% |
| Net margin | -6700.9% | 160.1% | -789.4% | -123.9% | -18.8% | -6.6% |
| Revenue growth | -96.0% | +2619.1% | -98.1% | +35.3% | +71.6% | — |
| Cash + short-term investments | $64.9M | $49.3M | $4.3M | $5.1M | $7.5M | — |
| Total debt | $188M | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 6.8x · P/B 0.8x · Earnings yield -0.97%

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +83.8% | -94.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +84.2% | -44.2% |
| Volatility (annualized) | 75.4% | 114.0% |
| Max drawdown | -34.3% (Jan 2026→Jun 2026) | -98.1% (Oct 2021→Mar 2025) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/TXMD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt